DiaMedica Inc. Share Price Toronto S.E.
Equities
DMA
CA25253T1075
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- CAD | - |
|
06-27 | Transcript : DiaMedica Therapeutics Inc. - Special Call | |
06-26 | DiaMedica Therapeutics Inc. Plans to Expand Its Clinical Trials into Preeclampsia | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 153M 112M 8.86B |
---|---|---|---|---|---|
Net income 2024 * | -35M -25.57M -2.02B | Net income 2025 * | -47M -34.33M -2.72B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.38
x | P/E ratio 2025 * |
-3.6
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.96% |
Latest transcript on DiaMedica Inc.
Managers | Title | Age | Since |
---|---|---|---|
Rick Pauls
CEO | Chief Executive Officer | 52 | 31/03/05 |
Scott Kellen
DFI | Director of Finance/CFO | 59 | 31/03/18 |
Ambarish Shah
CTO | Chief Tech/Sci/R&D Officer | - | 30/04/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Kuntz
BRD | Director/Board Member | 66 | 29/05/23 |
Tanya Lewis
BRD | Director/Board Member | 53 | 28/02/23 |
James Parsons
BRD | Director/Board Member | 58 | 19/10/10 |
1st Jan change | Capi. | |
---|---|---|
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- DMAC Stock
- DMA Stock